Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
about
Clostridium difficile phages: still difficult?Discovery and Development of NVB302, a Semisynthetic Antibiotic for Treatment of Clostridium difficile InfectionThe Challenge and Potential of Metagenomics in the ClinicRecent advances in the understanding of antibiotic resistance in Clostridium difficile infectionFidaxomicin: A novel agent for the treatment of Clostridium difficile infectionMetabolomics analysis identifies intestinal microbiota-derived biomarkers of colonization resistance in clindamycin-treated mice[Clostridium difficile infections in geriatric patients].Clostridium difficile infection: New insights into therapeutic options.Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model.Novel riboswitch-binding flavin analog that protects mice against Clostridium difficile infection without inhibiting cecal flora.How Do Small Things Make a Big Difference? Activities to Teach about Human-Microbe InteractionsNovel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies.Combined effects of oligofructose and Bifidobacterium animalis on gut microbiota and glycemia in obese rats.Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.Structure and function of a Clostridium difficile sortase enzymeMaternal high-protein or high-prebiotic-fiber diets affect maternal milk composition and gut microbiota in rat dams and their offspring.Clostridium difficile: improving the prevention paradigm in healthcare settings.Severe community onset healthcare-associated Clostridium difficile infection complicated by carbapenemase producing Klebsiella pneumoniae bloodstream infection.Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection.Differences of the Fecal Microflora With Clostridium difficile Therapies.A host-microbiome interaction mediates the opposing effects of omega-6 and omega-3 fatty acids on metabolic endotoxemia.Recurrent Clostridium difficile infection: From colonization to cure.Clostridium difficile drug pipeline: challenges in discovery and development of new agentsImpact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial.Breakthroughs in the treatment and prevention of Clostridium difficile infection.Fecal transplant in refractory Clostridium difficile colitis.The Antimicrobial Stewardship Approach to Combating Clostridium Difficile.A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin.Effect of Surotomycin, a Novel Cyclic Lipopeptide Antibiotic, on Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.Emerging therapies for Clostridium difficile infection - focus on fidaxomicin.Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian OutcomesEffect of Fidaxomicin versus Vancomycin on Susceptibility to Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.Short- and long-term effects of oral vancomycin on the human intestinal microbiota.Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.Treatment of recurrent Clostridium difficile infection: a systematic review.Clinical update for the diagnosis and treatment of Clostridium difficile infection.Variations in virulence and molecular biology among emerging strains of Clostridium difficile.Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile.Clostridium difficile: Changing Epidemiology, Treatment and Infection Prevention Measures.Probiotics in Clostridium difficile infection: reviewing the need for a multistrain probiotic.
P2860
Q21131097-1E967FF3-1F0B-4394-BACE-19070818F44DQ22337439-637204EF-E449-4E29-BA31-7C5CB6F2C39CQ26766414-7607A6C9-0C68-435D-8070-FBBBC7BA8763Q26767079-7AFB6A21-0DF9-467C-9812-7667B7C4B1ECQ26770175-9A341091-DDDD-47AF-8D23-7AC5A081684EQ27321016-65F6AA23-8A3A-4738-9665-88657813FCE2Q30244040-4AB3665A-11DE-4DB3-8395-096B81D364C5Q30252154-A82D87C7-97CE-473E-948D-323FBEF8006CQ30277636-53E039FF-E626-42B5-B848-4A6FDA026E1BQ34044442-D1078CBC-E14B-4B4A-956A-C238731E3457Q34703650-012113C6-680C-4486-AA4F-655BAA639001Q34801881-D5BDD767-58BE-4A54-87E5-00104C04C5DCQ35016733-53932AC3-E539-452C-AC3F-484F61485D7DQ35044119-F06C3111-908A-4EE4-974E-384D54290B86Q35210713-B3BA2902-A7D8-4680-B190-6BC250509EA6Q35212112-0FC6063E-2833-4CA8-8F28-23D2B7267CC0Q35222472-AA9FE22C-CBB8-4AE7-B34A-3EB76BC23E3FQ35236296-5B6259C5-7A40-448B-AFFA-5F4C5FD9EE82Q35605686-954492DF-5325-4A3F-AA06-479D790113F7Q35617263-6590257A-14AE-43E7-B81A-46CEBF7C1B1FQ35660484-6C4ECC61-8F06-4539-9ABD-843BD589AB00Q35822541-90432BAB-DD3D-4D2F-8C60-19AA031CCEB4Q35846436-4A6678AE-E997-4CD2-BABD-3866596301DDQ35898582-3939613C-9D18-4EC7-BC34-757DE848DCE5Q35918566-320E542A-42D3-4D8C-A4F0-6175A93FEFBCQ36647979-F94604D3-D5BC-4724-8A31-FE2512261472Q36683557-735CB8FE-B09F-485C-B88E-8A7AC96F89BEQ36793747-2ACA7115-0CA0-4189-BDAF-CA7DB7177828Q36933317-C8E3EF48-141A-4F90-811D-5615DFEAF7A8Q36984883-F1780A37-E3B0-4C5C-8ED2-FBCC285E588FQ36996876-1C931A41-F828-4BE8-A41A-F847B2C7B221Q37023290-32ADF59F-6F37-41E5-99F4-0516CA3949BBQ37509525-24F177C9-1429-4CE7-9AFD-08EB7DA4D98BQ37588248-66FFA84A-6369-46C6-A0A2-AF39ED0B03D3Q37602531-5FB13E0C-A562-41D4-84A2-8380DC32E38BQ37633859-AD2E0373-626A-4622-9362-39217037968FQ37680481-D0464656-5AD8-4FF8-AC32-85E007BE97ACQ37696597-EF201D19-A22E-4303-8E63-E4D18189B78FQ38051245-D275A8D0-95CC-4148-B68B-79C80B721E0FQ38084050-47B912F3-C312-461C-A23B-330536EF44C6
P2860
Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Fidaxomicin preserves the inte ...... ression and recurrence of CDI.
@ast
Fidaxomicin preserves the inte ...... ression and recurrence of CDI.
@en
type
label
Fidaxomicin preserves the inte ...... ression and recurrence of CDI.
@ast
Fidaxomicin preserves the inte ...... ression and recurrence of CDI.
@en
prefLabel
Fidaxomicin preserves the inte ...... ression and recurrence of CDI.
@ast
Fidaxomicin preserves the inte ...... ression and recurrence of CDI.
@en
P2093
P2860
P921
P356
P1476
Fidaxomicin preserves the inte ...... ression and recurrence of CDI.
@en
P2093
Brendan Byrne
Judy Emery
Kris Cannon
Linda Ward
Melissa Eyben
Thomas J Louie
Walter Krulicki
P2860
P304
P356
10.1093/CID/CIS338
P407
P478
55 Suppl 2
P577
2012-08-01T00:00:00Z